Audiomedica.com
Pembrolizuab Monotherapy Extended Survival in Advanced Lung Cancer
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 14:00:00
- Mas informaciones
Informações:
Sinopsis
CHICAGO, IL—Patients whose non-small cell lung cancers (NSCLC) expressed more than one per cent of the programmed death ligand-1 (PD-L1) tumor proportion score (TPS) lived longer when treated with the anti programmed death 1 (PD-1) antibody pembrolizumab than a control …AJO Gilberto Lopes and John Heymach PRODUCTION MASTER
